Bimuno is a ‘second generation’ galactooligosaccharide with prebiotic properties, which means it is not destroyed, digested or absorbed in the stomach or small intestine. It therefore reaches the colon intact to selectively target and feed the body's immunity boosting bifidobacteria while reducing harmful bacteria.
As a result, a recent study by the Imperial College Healthcare NHS Trust, Central Middlesex Hospital and the University of Reading, published in the Alimentary Pharmacology & Therapeutics found that those IBS patients taking Bimuno had significantly less bloating and abdominal pain, with some also reporting reduced anxiety scores and better quality of life.

The research also examined Bimuno's effect on the gut flora of IBS patients aged between 18 and 80, finding that it was able to stimulate bifidobacteria – natural ‘good’ bacteria and reduce the level of some harmful bacteria, including strains of Clostridium and Bacteroides.

The 12-week trial involved 44 patients who met the Rome II criteria for the diagnosis of IBS. Professor Nick Read, medical director of the Gut Trust commented: 'We are very encouraged to see the positive results of this trial, and welcome any new scientifically proven methods for treating IBS.’

Read more

www.bimuno.com

Click here for more research on the management IBS

Top of page